Medline Inc.
MDLNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 2/3060% above fair value
$37.04−0.80 (-2.11%)
Close on Nov 20, 2026Market cap $48.70BP/E –Yield –
Medline EBITDA Adjustment — Stock-Based Compensation by Quarter
EBITDA Adjustment — Stock-Based Compensation ($M)
Medline EBITDA Adjustment — Stock-Based Compensation: $29M in Q3 2026, up 93.3% from a year earlier.
Latest, Q3 2026
29
Period ended Sep 30, 2026
Change on a year earlier
+93.3%
15 in Q3 2025
History
7 quarters
Since Q1 2025
Sources
4
Documents cited below
Where the Q3 2026 figure comes from
Source: SEC Form 10-Q (FY2026Q3, filed 2026-11-04) ↗
Reported in SEC Form 10-K & Form 10-Q Segment Footnotes (XBRL).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | EBITDA Adjustment — Stock-Based Compensation ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 29 | +93.3% | SEC Form 10-Q (FY2026Q3, filed 2026-11-04) ↗ |
| Q2 2026 | Jun 30, 2026 | 29 | +93.3% | SEC Form 10-Q (FY2026Q2, filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 23 | +4.5% | SEC Form 10-Q (FY2026Q1, filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 27 | – | SEC Form 10-K FY2025 (filed 2026-03-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 15 | – | SEC Form 10-Q (FY2026Q3, filed 2026-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 15 | – | SEC Form 10-Q (FY2026Q2, filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 22 | – | SEC Form 10-Q (FY2026Q1, filed 2026-05-06) ↗ |
Cite this data
StockData. (2026). Medline EBITDA Adjustment — Stock-Based Compensation ($M), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Medline SEC filings and investor materials. https://stockdatahq.com/stocks/mdln/kpis/ng-adj-sbc
See every metric in the Medline KPI table. Data updated Nov 7, 2026.
See a number that looks wrong?